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Abstract
Most trials of antimalarials occur in areas where reinfections are possible. For Plasmodium
falciparum, reinfections are distinguished from recrudescences by PCR analysis of 3 polymorphic
genes. However, the validity of this approach has never been rigorously tested. We tested for
misclassification in 6 patients from clinical trials in Thailand and Cambodia who were classified as
reinfected by the standard PCR protocol. Using heteroduplex tracking assays and direct DNA
sequencing, we found that 5 of 6 (83%) patients were misclassified. Misclassification in this manner
overestimates the efficacy of antimalarials and delays recognition of decreasing therapeutic efficacy,
thus delaying potential policy changes.
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Drug-resistant Plasmodium falciparum malaria continues to be a growing health problem
through most of the world, thus making the development of new antimalarial drugs of vital
importance [1]. Antimalarial clinical trials are often carried out in areas where malaria is
endemic and patients who are successfully treated can potentially be reinfected during follow-
up. Thus, antimalarial efficacy can only be evaluated if reinfections can be distinguished from
recrudescences, a process complicated by the fact that these patients are usually infected with
a mixture of genetically distinct variants [1–4].
A recent expert panel proposed distinguishing recrudescence from reinfection using PCR
amplification and agarose gel electrophoresis of 3 polymorphic genes: merozoite surface
protein 1 (msp-1), merozoite surface protein 2 (msp-2) and glutamine-rich protein (glurp) [5].
The report suggested that “a new infection is defined as subsequently occurring parasitemia in
which all alleles in the post treatment sample of a patient are completely different from those
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in the admission sample for one or more loci tested [5].” It also proposes that a recurrent
parasitemia be classified as a recrudescence if at least one allele at each locus is common to
paired pre and post-treatment samples. However, there are few well controlled evaluations of
these definitions. We have previously shown that this assumption may be incorrect in high
transmission areas where a small number of variants predominate [4].
The currently recommended strategy involves sequential analysis of the three genes from most
polymorphic, msp-2 or glurp, to least polymorphic, msp-1 [5]. However, it is clear that the
discriminatory ability of this procedure to identify unique variants is questionable [4,6]. The
use of three markers is meant to overcome these issues. However, it has been suggested that
increasing the number of markers used may increase that chance that a given variant might not
be amplified at one of the markers [7]. Thus, using fewer sites with methods that better describe
the diversity at each site could be beneficial [5].
Within any patient, the complexity of infection (COI) can be high, with as many as 13 variants
seen in a given sample [4]. Many variants may represent <20% of the total parasite population
(minority variants). It has been shown that nested PCR and PCR analysis with sequencing are
insensitive to these minority variants in malaria and other polyclonal infections, such as HIV
[6,8–10]. Therefore, shared msp-1, msp-2 or glurp variants could potentially be missed leading
to misclassification of recrudescences as reinfections, thus over-estimating drug efficacy.
Heteroduplex tracking assays (HTAs), an alternative genotyping strategy, are able to detect
minority variants and both size and sequence polymorphism [4,6,11]. We have previously used
a HTA of msp-1 block 2 to describe COI in areas of low and high malaria transmission and
describe a new msp-2 HTA assay here [4,11].
In order to determine if standard genotyping methods are misclassifying recrudesences as
reinfections, we evaluated paired enrollment and recurrent parasitemia samples from 12
patients in two studies: 1) a Phase II clinical trial of DB-289 at the Hospital for Tropical
Diseases in Bangkok, Thailand and 2) an in vivo efficacy study of artesunate-mefloquine in
Chumkiri, Cambodia. All of these patients had little to no chance of reinfection clinically. We
compared two criteria for the classification of enrollment and recurrent parasitemias: 1)
classification of the samples by msp-1, msp-2, and glurp PCR, as recommended by the MMV/
WHO report [5] or 2) by HTA analysis of the samples at two sites, msp-1 and msp-2. Using
both methods, recurrences were classified as reinfections if shared bands were absent from any
gel comparing enrollment and recurrent infections as recommended by the WHO/MMV report.
Pre- and post-treatment samples from 6 patients classified as reinfection by standard PCR, as
well as a pre and post treatment samples from 6 patients classified as recrudesences, were
studied.
Patients, materials, and methods
P. falciparum DNA was extracted from paired de-identified dried blood spots at enrollment
and recurrence of parasitemia. Informed consent was received from all patients in both trials.
Twenty eight patients in the Phase II clinical trial (Thailand) and 31 patients in the in vivo
clinical efficacy study (Cambodia) experienced recurrent parasitemia. Details of the studies
are included in the on-line supplemental material and will be published elsewhere. PCR
analysis of msp-1, msp-2 and glurp was completed on all samples. The PCR methods have
been described previously [12]. Gels were reviewed independently by two authors.
In total, six patients from these two trials were classified as reinfection by PCR (Table 1). In
addition to the six sample pairs classified as reinfection, six sample pairs classified as
recrudesences were also selected for analysis by HTA. There were no significant differences
in the characteristics of the patients classified as reinfection or recrudescence, or between the
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patients from Thailand and Cambodia (see on-line supplemental material). Of note, all four
patients from the Phase II trial in Bangkok never left the hospital before the recurrence of
parasitemia. Bangkok is not a transmission zone for malaria and therefore these patients had
no risk of reinfection. The patients from the in vivo clinical efficacy trial in Cambodia did not
remain in the hospital during their follow-up and were therefore at risk for reinfection.
However, the risk of local reacquisition was low.
The msp-1 HTA was carried out as previously described in the literature [11]. For this study,
a new msp-2 HTA was developed (assay development and validation are described in the
Supplementary Material). Each sample was analyzed in duplicate to ensure the accuracy of the
results and reliability of the assay. Bands were interpreted based on criteria established in the
literature and considered significant only if they were present in both replicates, represented
>3% of the total parasite population, and were visible to the eye [4,13].
Results
Standard PCR methods for the three markers classified six patients as reinfections and six
patients as recrudescences based upon the MMV/WHO criteria. Of the six patients classified
as reinfections, two lacked shared bands at msp-2, two lacked shared bands at glurp, and two
lacked shared bands in both. However, HTAs detected shared bands in 5 of the 6 patients
suggesting that only one patient was reinfected (Table 1). All patients classified as
recrudescences by nested PCR were also classified as recrudescences by HTA.
This difference is due to the ability of HTAs to detect variants that are missed by standard PCR
methods [4,6,11]. The msp-1 HTA detected an average of 3.1 bands, as compared to 1.8 bands
by PCR (paired t-test, p=0.003). At msp-2, the HTA and PCR detected on average 4.5 bands
compared to 1.8 bands, respectively (paired t-test, p=0.0001).
The shared variants which are missed by standard PCR are “minority variants” representing
<20% of the parasite population. For example, in one patient sample pair (Figure 1, Lanes A-
D), the shared variant represented only 14.5% of the initial parasite population and 10.6% of
the recurrent parasitemia parasite population. This phenomenon was seen in all three sample
pairs that were misclassified at msp-2 (Legend of Figure 1).
Two of the patients classified as reinfections by PCR, Thailand patients 14 and 29, could not
have been reinfected, since they never left the hospital in Bangkok. Sequence analysis of
variants from Thailand patient 29 confirmed a shared variant (Genbank Accession Number:
EU331092). The details of this analysis are provided in the Supplementary Material.
Discussion
In this study, we show that standard PCR methods for genotyping recurrent parasitemias can
misclassify recrudescent parasitemias as reinfections. We found that 5 of 6 (83%) of samples
classified as reinfection by the WHO/MMV scheme in this study were more likely to be
recrudesences. Even if the two patients who were classified as reinfection because of not
sharing a band at glurp by standard PCR are removed, 3 of the other 4 (75%) samples would
still be misclassified. This misclassification is an inherent problem of the standard PCR assays
due to their inability to detect minority variants. This is important because misclassification in
this manner overestimates drug efficacy. Thus, this type of misclassification might delay
needed switches in first-line antimalarial policy, which the WHO recommends when 28 day
efficacy falls below 90% [14].
This study involves a relatively small number of patients. However, the patients from the Phase
II clinical trial are unusual in that all those presented here failed while remaining in the hospital
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in Bangkok without risk of reinfection. Thus, they provide a unique opportunity for determining
misclassification of recrudescences as reinfections. The expense of keeping patients in hospital
during clinical trials means this method cannot be employed by most trials to prevent
reinfection and therefore the availability of this type of clinical sample is limited.
The use of multiple markers in a step wise approach may increase the probability of a
recrudescence being misclassified as a reinfection due to the increased chance that at least one
marker will fail to detect a shared minority variant [4,15]. If assays that are sensitive to minority
variants are used, such as HTAs, fewer loci may be needed to accurately classify samples.
However, defining how many markers are appropriate would require further investigation.
The results of this study show that minority variants occur frequently, even in regions of
relatively low transmission, and may cause a significant amount of misclassification of
recurrent parasitemias with the WHO/MMV recommended methods. It suggests that using
traditional PCR correction methods in regions of low transmission may be detrimental as
clinical efficacy of a drug may be overestimated. Assays sensitive to minority variants, such
as HTAs, capillary electrophoresis and other fragment analysis techniques, may therefore be
better suited for correcting clinical trials in areas of low transmission. Currently, it is unclear
if this same problem exists in regions with high transmission and further investigation of this
is warranted.
In addition to the problem of misclassifying reinfections describe here, we also need to worry
about misclassifying recrudescences [4]. In some areas, specific variants are present at a high
prevalence. Because of this, patients who are reinfected by the same variant that was present
before treatment could be misjudged as recrudescences. This can be adjusted for statistically
if the prevalence of the various variants are measured [4].
The msp-2 HTA developed for this study provided an accurate and quantitative representation
of the variants within the clinical sample. Nevertheless, it clear that this method still has
limitations. Within some recurrent parasitemias, major variants can exist which were not
detected in the initial parasitemia. For example, in Figure 1 Lanes C and D, the majority variant
based on phosphorimager intensity (R1) was not detected in the initial parasitemia. These are
likely variants that initially existed below the limit of detection of the assay or were sequestered
at the time of initial sampling. Another possibility is that these variants existed in a pre-
erythrocytic stage at the time of therapy. However, given that failures occurred at Days 19–35
in these six patients it is unlikely. Thus, new technologies and protocols for sampling should
continue to be investigated. Technical limitations of HTAs also need to be considered. PCR
with agarose gel electrophoresis is technically simple, does not require expensive equipment,
and is easily done in the developing world. The major disadvantage of HTAs is that they require
the use of radioactive probes, which limits their use in developing countries because there are
few facilities with permits to handle radioactive waste disposal. However, probes can
potentially be labeled with non-radioactive labels, such as fluorescent tags or biotinylation.
More extensive discussions of the advantages and disadvantages of HTAs have been published
elsewhere [4,6].
This study is the first report showing strong evidence for the misclassification of recrudesences
as reinfections in antimalarial trials using the currently recommended MMV/WHO protocols.
Unfortunately, the rate of misclassification we found was high. Due to this problem, the
interpretation of PCR genotyping in its current form should be done with caution. In the future,
we need to continue to work on improving the techniques and protocols used for classifying
recurrent parasitemias.
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Figure 1. msp-2 HTA of Three Sample Pairs Misclassified by Standard PCR
Each of these three patient sample pairs was classified as containing no shared variant at
msp-2 by standard PCR. Paired samples were run in duplicate for each patient. The initial two
lanes (A, B, E, F, I, and J) in each gel show the initial parasitemia. The second two lanes (C,
D, G, H, K and L) contain the recurrent parasitemias. At least one shared minority variant was
detected in all three sample pairs by HTA (marked with “*”). In Thailand Patient 14, the shared
variant represented 14.5% of the initial parasitemia and 10.6% of the recurrent parasitemia as
detected by exposure of the gel to a phosphorimager. Thailand Patient 29 contained a shared
variant representing 14.0% and 11.2% of the initial and recurrent parasitemia, respectively.
Two shared variants were found in Cambodia Patient 46. The first represented 10.8% and
22.7% of the initial and recurrent parasitemia, respectively. The second represented 4.9% and
25.6%, repectively. The shared minority variant on Thailand Patient 29 was confirmed by
sequencing [Genbank Accession Number: EU331092].
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